OSU as a Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

• 批准号: 10356923
• 负责人: DAVID P. CARBONE
• 金额: $ 108.37万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-28 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10356923
• 关键词: Address; Adult; Advisory Committees; Affect; Area; Award; Basic Science; Biochemistry; Biological Markers; Biomedical Research; Biometry; Biotechnology; CEBPA gene; Cancer Biology; Cancer Center; Cancer Hospital; Cancer Patient; Center for Translational Science Activities; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Oncology Supplement (K12); Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Comprehensive Cancer Center; Contracts; Data; Databases; Decitabine; Discipline; Disease; Education; Educational process of instructing; Educational workshop; Enrollment; Environment; Epidemiologist; FLT3 gene; Faculty; Fostering; Funding; Generations; Goals; Grant; Growth; Gynecologic Oncology; Health Personnel; Hematologic Neoplasms; Hematology; Hematopoietic Neoplasms; Image; Immunologics; Immunology; Infrastructure; Inpatients; Institutes; Investigational Therapies; Knowledge; Laboratory Scientists; Lead; Leadership; Learning; Malignant Neoplasms; Medical; Medical Oncology; Mentors; Modeling; Molecular Genetics; NCI Center for Cancer Research; National Clinical Trials Network; Nurses; Oblimersen; Ohio; Operative Surgical Procedures; Outcome; Outpatients; Pathologist; Patient-Focused Outcomes; Patients; Peer Review; Pentostatin; Performance; Pharmacists; Pharmacology; Phase; Physicians; Postdoctoral Fellow; Protocols documentation; Psychiatrist; Quality of life; Radiation Oncologist; Radiation Oncology; Radiation therapy; Research; Research Activity; Research Design; Research Institute; Research Personnel; Resources; Science; Scientist; Site; Solid Neoplasm; Structure; Support Groups; Surgical Oncologist; Surgical Oncology; Symptoms; Therapeutic; Therapeutic Agents; Time; Tissues; Toxic effect; Training; Translating; Translational trial; Tumor Biology; Universities; base; cancer clinical trial; cancer prevention; cancer therapy; career; career development; college; confirmatory trial; data submission; design; doctoral student; drug development; efficacy evaluation; experience; high standard; improved; improved outcome; innovation; investigator-initiated trial; lenalidomide; leukemia; meetings; minority patient; multidisciplinary; multimodality; next generation; novel; novel therapeutics; operation; patient population; pre-clinical; pre-doctoral; preclinical study; programs; recruit; research study; risk stratification; rituximab; success; targeted treatment; translational scientist; translational therapeutics; treatment trial; tumor heterogeneity; volunteer

PROJECT SUMMARY The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU) participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching and mentoring within the NCTN, and 9) enroll volunteering patients on trials.

项目摘要 此应用程序的目标是提供支持俄亥俄州州立大学（OSU）的基础设施 作为网络领导者参与NCI的NCTN计划的科学和临床研究活动 学术参与网站（OSU-LAPS）。来自俄勒冈州立大学的教师被整合到科学和行政 活动，参加会议，管理多个核心实验室，设计研究并在所有现有的 成人NCTN网络组使用OSU综合癌症中心（OSUCCC）资源， 资源OSUCCC研究人员开发并领导旨在招募多学科患者的研究 治疗试验以及开发和执行相关的科学相关的研究，带来特殊的 在血液恶性肿瘤和实体瘤方面的专业知识。我们的医疗，血液，外科和放射 肿瘤学家、移植者、精神病学家、病理学家、细胞遗传学家、转化和基础实验室 科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员帮助制定 临床和基础科学问题，其答案有助于改善患者结局， 了解肿瘤生物学。OSU-LAPS将为OSU患者人群提供创新的NCI试验，支持 肿瘤生物学的科学发现，找到更好的治疗方法，提高患者的生活质量， 改善影响成年人的各种癌症的结果。该综合方案旨在：1） 在I期至III期NCI临床试验中研究新的治疗药物及其毒性; 2）评估疗效 和毒性，以更有效地开发协同组合; 3)发展多模式的方法，使用手术，免疫和放射治疗， 结合; 4）整合分子遗传学，生物化学，药理学，免疫学， 生物统计学在治疗方案的设计和执行; 5）通过发现改善癌症的结果 和教育的前和博士后学生，护士，专职医疗人员和医生，6）了解 并利用肿瘤异质性，充分发挥靶向治疗的价值，7）改善 癌症相关的症状，8）通过为他们提供正式的教学，形成下一代的临床研究人员 在NCTN内进行指导，以及9）招募志愿患者参加试验。